Navigation Links
InterMune to Release Third Quarter Financial Results on November 3
Date:10/27/2011

BRISBANE, Calif., Oct. 27, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2011 financial results at the close of the U.S. markets on Thursday, November 3, 2011.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 22885421.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 22885421.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
2. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
3. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
4. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune Reports Third Quarter 2010 Financial Results
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. InterMune to Release Second Quarter Financial Results on July 27
9. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
10. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
11. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) ... to encourage inner healing of memories and achieve forgiveness, through a progressive journey ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Momkus McCluskey ... newest Partner. Ms. Parks is a member of the firm’s Commercial Litigation and Employment ... and provides a wealth of knowledge in matters of employment litigation, commercial litigation and ...
(Date:8/17/2017)... ... 2017 , ... A recent report indicates that circa 79 percent of 483 ... in data integrity. The FDA outlines their expectations for quality critical instrumentation in the ... of the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, this ...
(Date:8/16/2017)... ... 2017 , ... Blue Health Intelligence (BHI) announced today that Dr. ... Spiro brings over 30 years of clinical, healthcare IT, value-based care, and change management ... , “I am thrilled to welcome Dr. Spiro to BHI,” said Swati Abbott, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...
Breaking Medicine News(10 mins):